Knight Therapeutics Ownership

Pink Sheets . USA . 
Stock . Knight Therapeutics
KHTRF Stock  USD 3.73  0.02  0.53%   
Knight Therapeutics maintains a total of 113.96 Million outstanding shares. Knight Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Knight Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Knight Therapeutics, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Knight Pink Sheet Ownership Analysis

About 31.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Knight Therapeutics recorded a loss per share of 0.04. The entity had not issued any dividends in recent years. Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada. Knight Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 660 people.The quote for Knight Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Knight Therapeutics contact the company at 514 484 4483 or learn more at https://www.gud-knight.com.

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Knight Pink Sheet

Knight Therapeutics financial ratios help investors to determine whether Knight Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY